An interventional study of MagPro X100 repetitive Transcranial Magnetic Stimulation and MagPro X100 repetitive Transcranial Magnetic Stimulation in Hallucinations, Schizophrenia and Perceptual Disorders, sponsored by University Hospital, Lille. Completed at 2 sites in France. Open to participants aged 13 Years to 60 Years. Per ClinicalTrials.gov, last updated 2025-12-26.
Sponsored by University Hospital, Lille · Not applicable, Interventional, and Treatment
136 studies on the registry are indexed under Hallucinations; 35 are open to participants now.
This study's enrollment of 85 is above the median of 48 across 118 interventional studies indexed under Hallucinations.
Browse Hallucinations studies →University Hospital, Lille is the lead sponsor of 631 studies on the registry; 142 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Device: MagPro X100 repetitive Transcranial Magnetic Stimulation
Device: MagPro X100 repetitive Transcranial Magnetic Stimulation
Target defined using both fMRI during hallucinations occurence and tractography. Parameters: 1 Hz/ 100% of the Motor Threshold/ 10 sessions (2/ day over 5 days)/ 1200 pulses/ session
Target: T3-P3 (10-20 EEG international System). Parameters: 1 Hz/ 100% of the Motor Threshold/ 10 sessions (2/ day over 5 days)/ 1200 pulses/ session
Severity and Frequency of Hallucinations
Visual Analogue Scale (Severity)/ Visual Analogue Scale (Frequency rate)
Time frame: Assessed at baseline (t0) and longitudinally after the 10 rTMS sessions during the following month (D+15, M+1, M+3, M+6, M+12)
Clinical State
Clinical Global Improvement \[CGI\]/ Positive \& Negative Symptoms Scale \[PANSS\]/ Global Assessment of Functioning \[GAF\]. For the auditory modality: Add the Auditory Hallucinations rating Scale \[AHRS\] frequency scale and total score/ Add the computerized Binary Scale of Auditory Speech Hallucinations \[cbSASH\]
Time frame: Assessed at baseline (t0) and longitudinally after the 10 rTMS sessions during the following month (D+15, M+1, M+3, M+6, M+12)
MRI changes
structural MRI/ functional MRI/ Diffusion Tensor Imaging/ MR-spectroscopy
Time frame: Assessed at baseline (t0) and 1 month after the rTMS sessions (M+1)
Plan to share: No
Ran from Nov 2010 to primary completion in Feb 2022, 134 months.
Of 53 non-industry interventional studies with no phase under Hallucinations, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 56. This study's 134 months is above that.
Counting every sponsor, half of 53 studies reached it within 37 months; a quarter within 20 and three quarters within 56.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.